AUG 10, 2026 · PHASE 1/2 TRIAL
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
ClinicalTrials.gov
This is a Phase 1b/2 trial registration with no results posted; the study is actively recruiting and designed to evaluate safety and efficacy of a novel agent in combination therapy for ER+/HER2− breast cancer.
Reported
Planned enrollment285
Phase Ib primary outcomeIncidence and Severity of Adverse Events, u…
Phase Ib primary outcomeNumber of Participants With Dose-Limiting T…